NASDAQ · FDMT
Healthcare · Biotechnology
$11.03
Up+$0.23 (+2.13%)
Updated Oct 27, 2026, 7:30 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · FDMT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
FDMT closed at $11.03 after 21 trading sessions, down 24.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $10.74 | $11.29 | $10.62 | $11.03 | 1.08M |
| Oct 23, 2026 | $11.74 | $11.75 | $10.675 | $10.80 | 996.14K |
| Oct 22, 2026 | $12.60 | $13.12 | $11.68 | $11.85 | 1.35M |
| Oct 21, 2026 | $13.12 | $13.45 | $12.605 | $12.62 | 2.02M |
| Oct 20, 2026 | $12.29 | $13.39 | $12.29 | $13.10 | 725.37K |
| Oct 19, 2026 | $12.36 | $12.68 | $12.21 | $12.29 | 855.68K |
| Oct 16, 2026 | $12.84 | $12.84 | $12.00 | $12.14 | 794.54K |
| Oct 15, 2026 | $12.30 | $13.01 | $12.0388 | $12.87 | 787.61K |
| Oct 14, 2026 | $12.18 | $12.58 | $11.99 | $12.20 | 632.96K |
| Oct 13, 2026 | $12.91 | $12.91 | $12.25 | $12.36 | 991.72K |
| Oct 12, 2026 | $13.30 | $13.4721 | $12.86 | $13.00 | 835.84K |
| Oct 9, 2026 | $12.70 | $13.85 | $12.55 | $13.33 | 868.09K |
| Oct 8, 2026 | $12.42 | $12.735 | $12.12 | $12.70 | 970.76K |
| Oct 7, 2026 | $12.36 | $12.92 | $12.185 | $12.59 | 603.57K |
| Oct 6, 2026 | $12.64 | $13.015 | $12.30 | $12.56 | 1.17M |
| Oct 5, 2026 | $13.86 | $13.86 | $12.61 | $12.92 | 2.11M |
| Oct 2, 2026 | $14.12 | $14.135 | $13.60 | $13.67 | 1.04M |
| Oct 1, 2026 | $14.23 | $14.58 | $13.80 | $13.84 | 655.46K |
| Sep 30, 2026 | $14.76 | $14.83 | $14.075 | $14.31 | 1.04M |
| Sep 29, 2026 | $14.70 | $14.97 | $13.935 | $14.49 | 1.38M |
| Sep 28, 2026 | $14.355 | $14.82 | $13.92 | $14.56 | 1.56M |
The latest Smart Investors Daily articles mentioning FDMT.
Company
Market Activity
Research & News
FDMT research
Company profile and research snapshot.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 22, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 6, 2026 | Chardan Capital | Buy | — |
| Sep 29, 2026 | B of A Securities | Buy | — |
| Sep 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 20, 2026
U.S. stock futures were mixed as GM shares fell 7.3% despite an earnings beat; FreightCar America, 4D Molecular and others also declined premarket.
Yahoo · Oct 16, 2026
EMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 13, 2026, the compensation committee of the Company’s board of directors granted 13 new non-executive employees options to purchase an aggregate of 260,000 shar
Benzinga · Oct 6, 2026
Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.
Yahoo · Oct 5, 2026
Company to share insights on the advancing clinical profile and commercial vision for 4D-150Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C. Awh, MD, FASRS; Dr. David Eichenbaum, MD, FASRS; and Dr. Sara J. Haug, MD, PhD, will join 4DMT leadership to offer perspective on transforming the treatment paradigm in VEGF-driven retinal diseasesLive event will take place in New York City on October 21, 2026 at 10:30am ET EMERYVILLE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- 4D M
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FDMT.
